Linthicum, MD - July 29, 2015 – Surgery is required when cancer of the kidney causes a Level III thrombus, or clot, to develop in the major vein leading back to the heart. Traditionally this complicated procedure, inferior vena cava (IVC) thrombectomy, is performed using a large open incision, primarily because the vein is often difficult to reach. In an article published in The Journal of Urology®, a team of surgeons describe the first cases in which this procedure has been successfully performed robotically, using only seven small incisions and four robotic tools.
“Level III IVC tumor thrombectomy for renal cancer is one of the most challenging open urologic oncologic surgeries,” explained Inderbir S. Gill, MD, of the USC Institute of Urology, part of Keck Medicine of USC in Los Angeles, CA. “While IVC tumor thrombus occurs in only 4-10% of all patients with otherwise organ-confined kidney cancer, surgery is the only cure. The ability to do this complicated procedure in a minimally invasive way represents a major advancement.”
The authors report on nine patients with renal cancer and Level III thrombi treated with robotic IVC thrombectomy. After about seven months of follow-up, all have survived and eight show no evidence of disease. One patient had a spinal tumor and has since undergone further surgery.
This report also details seven additional robotic surgeries on patients with smaller thrombi (Level II), and compares tumor sizes, operating room times, blood losses, length of hospital stays, and other details for Level III and Level II cases.
Because the surgery involves removal of the thrombus as well as removal of the diseased kidney, the surgeon must remove the clot first to prevent it from breaking off and causing a potentially fatal embolism. This requires many blood vessels to be clamped as shown in the diagram. This diagram also indicates the extent of Levels I, II and III thrombi, and the relative sizes of the obstructions.
“All necessary surgical maneuvers could be performed completely robotically without open conversion or mortality. This demonstration of efficient robotic performance of the challenging vascular, oncologic and reconstructive procedures inherent herein opens the door for major renal, caval, and hepatic robotic surgeries in the future. Although our experience is yet initial, we believe that robotic IVC thrombus surgery has considerable potential for the future,” commented Dr. Gill and the team.
# # #
NOTES FOR EDITORS
“Robotic Level III Inferior Vena Cava Tumor Thrombectomy: The Initial Series,” by Inderbir S. Gill, Charles Metcalfe, Andre Abreu, Vinay Duddalwar, Sameer Chopra, Mark Cunningham, Duraiyah Thangathurai, Osamu Ukimura, Raj Satkunasivam, Andrew Hung, Rocco Papilla, Monish Aron, Mihir Desai, and Michele Gallucci. DOI: http://dx.doi.org/10.1016/j.juro.2015.03.119. Published online in advance of The Journal of Urology®, Volume 194, Issue 4 (October 2015) by Elsevier.
Full text of this article is available to credentialed journalists upon request; contact Linda Gruner at 212-633-3923 or email@example.com to obtain copies. Journalists wishing to interview the authors should contact Leslie Ridgeway, Media Relations Specialist, at 323- 442-2823 or firstname.lastname@example.org.
ABOUT THE JOURNAL OF UROLOGY®
Established in 1917, The Journal of Urology® (www.jurology.com) is the official journal of the American Urological Association (www.auanet.org). It is the most widely read and highly cited journal in the field. It brings to its readership all the clinically relevant information needed to stay at the forefront of this dynamic field. This top-ranking journal presents investigative studies on critical areas of research and practice, survey articles providing short condensations of the best and most important urology literature worldwide and practice-oriented reports on interesting clinical observations.
Elsevier (www.elsevier.com) is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect (www.sciencedirect.com), Scopus (www.scopus.com), Elsevier Research Intelligence (www.elsevier.com/research-intelligence), and ClinicalKey (www.clinicalkey.com) — and publishes over 2,500 journals, including The Lancet (www.thelancet.com) and Cell(www.cell.com), and more than 33,000 book titles, including a number of iconic reference works. Elsevier is part of RELX Group plc (www.relxgroup.com), a world-leading provider of information solutions for professional customers across industries. www.elsevier.com
Christine Frey, AUA